Cosmo Issues EUR 175 million Convertible Bond
Cosmo Pharmaceuticals N.V. announces that it has successfully placed EUR 175 million senior unsecured convertible bonds (the “Bonds”) due 2023. The net proceeds from the Offering will be used for general corporate purposes, potential acquisitions and
in-licensing transactions.